BRPI0814256A2 - Inibidores de tetrahidropiranocromeno gama secretase - Google Patents

Inibidores de tetrahidropiranocromeno gama secretase

Info

Publication number
BRPI0814256A2
BRPI0814256A2 BRPI0814256-4A2A BRPI0814256A BRPI0814256A2 BR PI0814256 A2 BRPI0814256 A2 BR PI0814256A2 BR PI0814256 A BRPI0814256 A BR PI0814256A BR PI0814256 A2 BRPI0814256 A2 BR PI0814256A2
Authority
BR
Brazil
Prior art keywords
tetrahydropyrochyromene
secretase
inhibitors
range
range inhibitors
Prior art date
Application number
BRPI0814256-4A2A
Other languages
English (en)
Inventor
Wen-Lian Wu
Thomas A Bara
Duane A Burnett
John W Clader
Martin S Domalski
Yan Jin
Hubert B Josien
Hongmei Li
Xian Liang
Dmitri A Pissarnitski
Thavalakulamgara K Sasikumar
Jesse K Wong
Ruo Xu
Zhiqiang Zhao
Paul Mcnamara
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0814256A2 publication Critical patent/BRPI0814256A2/pt
Publication of BRPI0814256A8 publication Critical patent/BRPI0814256A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BRPI0814256A 2007-07-05 2008-07-01 Inibidores de tetrahidropiranocromeno gama secretase BRPI0814256A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94803307P 2007-07-05 2007-07-05
PCT/US2008/008192 WO2009008980A2 (en) 2007-07-05 2008-07-01 Tetrahydropyranochromene gamma secretase inhibitors

Publications (2)

Publication Number Publication Date
BRPI0814256A2 true BRPI0814256A2 (pt) 2015-02-03
BRPI0814256A8 BRPI0814256A8 (pt) 2016-02-10

Family

ID=39830164

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814256A BRPI0814256A8 (pt) 2007-07-05 2008-07-01 Inibidores de tetrahidropiranocromeno gama secretase

Country Status (16)

Country Link
US (1) US8664411B2 (pt)
EP (1) EP2435416B1 (pt)
JP (1) JP5240871B2 (pt)
KR (1) KR20100044197A (pt)
CN (1) CN101754960A (pt)
AR (1) AR067445A1 (pt)
AU (1) AU2008275735B2 (pt)
BR (1) BRPI0814256A8 (pt)
CA (1) CA2691542A1 (pt)
CL (1) CL2008001960A1 (pt)
CO (1) CO6270309A2 (pt)
EC (1) ECSP109845A (pt)
PE (1) PE20090435A1 (pt)
RU (1) RU2483061C2 (pt)
TW (1) TW200908959A (pt)
WO (1) WO2009008980A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702044A (zh) 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
EP2178882B1 (en) 2007-07-17 2013-04-17 Merck Sharp & Dohme Corp. Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
WO2012138678A1 (en) * 2011-04-04 2012-10-11 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
US9226927B2 (en) * 2011-09-09 2016-01-05 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
EP2925313A4 (en) * 2012-11-29 2016-05-11 Merck Sharp & Dohme SPIROCYCLIC SULPHONES AS GAMMA SECRETASE INHIBITORS
AU2013366668B2 (en) * 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
ES2612215T3 (es) 2013-01-17 2017-05-12 Janssen Pharmaceutica, N.V. Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
AR110152A1 (es) * 2016-11-09 2019-02-27 Bristol Myers Squibb Co SULFONAS TRICÍCLICAS COMO MODULADORES DE RORg
EP3634978A1 (en) 2017-06-07 2020-04-15 Adrx, Inc. Tau aggregation inhibitors
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
FR2827590B1 (fr) * 2001-07-18 2003-10-24 Atuser Transbordeur de liquides alimentaires usages
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
AR034390A1 (es) 2001-08-03 2004-02-25 Schering Corp Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa
RU2202370C1 (ru) * 2001-12-26 2003-04-20 Эпштейн Олег Ильич Нейропсихотропное лекарственное средство
GB0222833D0 (en) 2002-10-02 2002-11-06 Syngenta Ltd Chemical process
GB0223039D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
MXPA05012323A (es) * 2003-05-16 2006-01-30 Merck Sharp & Dohme Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
GB0317491D0 (en) * 2003-07-25 2003-08-27 Novartis Ag Organic compounds
DE102005062098A1 (de) * 2005-12-22 2007-06-28 Merck Patent Gmbh Oxaphenanthren-Derivate
CN102702044A (zh) * 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
TW200813054A (en) * 2006-06-02 2008-03-16 Elan Pharm Inc Fused, tricyclic sulfonamide inhibitors of gamma secretase
MX2011005046A (es) 2008-11-13 2011-06-01 Schering Corp Moduladores de gamma secretasa.

Also Published As

Publication number Publication date
KR20100044197A (ko) 2010-04-29
EP2435416A2 (en) 2012-04-04
JP5240871B2 (ja) 2013-07-17
PE20090435A1 (es) 2009-04-18
CA2691542A1 (en) 2009-01-15
US8664411B2 (en) 2014-03-04
AR067445A1 (es) 2009-10-14
TW200908959A (en) 2009-03-01
CL2008001960A1 (es) 2009-11-27
AU2008275735B2 (en) 2014-03-27
EP2435416B1 (en) 2016-03-30
ECSP109845A (es) 2010-02-26
WO2009008980A3 (en) 2009-03-19
AU2008275735A1 (en) 2009-01-15
RU2483061C2 (ru) 2013-05-27
BRPI0814256A8 (pt) 2016-02-10
CO6270309A2 (es) 2011-04-20
RU2010103716A (ru) 2011-08-10
WO2009008980A2 (en) 2009-01-15
US20110236400A1 (en) 2011-09-29
JP2010532359A (ja) 2010-10-07
AU2008275735A2 (en) 2010-02-11
CN101754960A (zh) 2010-06-23

Similar Documents

Publication Publication Date Title
BRPI0814256A2 (pt) Inibidores de tetrahidropiranocromeno gama secretase
FR20C1030I2 (fr) Inhibiteurs de beta-lactamase
BRPI0815135A2 (pt) Derivados de azepina como inibidores de gama secretase.
CY2017016I1 (el) Αναστολεις πρωτεασωματος
BRPI0812170A2 (pt) Moduladores de gama secretase
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
EP2305306A4 (en) NEURO INVASION INHIBITOR
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
BRPI0810832A2 (pt) Ferramenta de nível
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
BRPI1011129A2 (pt) métodos e compostos inibidores de janus cinase
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
BRPI0719499A2 (pt) Composições de poliolefina
EP2046887A4 (en) Light-Crosslinkable Polyolefin Compositions
EP2192838A4 (en) HETEROCYCLIC NEKROPTOSIS HEMMER
BRPI0918564A2 (pt) inibidores
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
BRPI0622049A2 (pt) Estimativa de estado dinâmico
DK2066662T3 (da) Serinhydrolaseinhibitorer
BRPI0716198A2 (pt) Pirrolo-isoquinolinas como inibidores de cinase
BRPI0806542A2 (pt) Derivados de sulfonamida como inibidores de quimase
EP2065439A4 (en) polyolefin
BRPI0812491A2 (pt) Moduladores de gama secretase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.